TransCanna’s TCM Distribution, Inc. Receives Adelanto Adult Use Permits For Manufacturing and Distribution
TransCanna Holdings Inc. (TransCanna) (CSE:TCAN) (XETR:TH8) (“TransCanna” or the “Company”) is pleased to announce the Company’s wholly owned subsidiary, TCM Distribution, Inc., has received an Adult Use Cannabis Manufacturing permit and an Adult Use cannabis distribution permit from the City of Adelanto, California.
As previously reported on April 18, 2019, TCM Distribution sub-leased 10,000 square feet of warehouse space in Adelanto. Thereafter, TCM Distribution applied for the above two referenced permits with the City of Adelanto which were received on May 28, 2019. TCM Distribution has applied for its state of California Adult Use permanent manufacturing license and distribution licenses, which are pending.
“The purpose of the Adelanto facility is two-fold; first, it’ll be used as one of our southern California satellite facilities for goods being transported from our 196,000 square foot vertically integrated, cannabis focused facility in Modesto. Second, with the non-volatility manufacturing license we’ll be able to accommodate the production and packaging of pre-rolled cannabis products and other products of similar nature, then distribute them accordingly,” stated Jim Pakulis, CEO of TransCanna.
“GoodFellas, one of the entities the Company is preparing to acquire, will be transferring all revenue generating distribution and manufacturing processes to Adelanto once the facility receives its Certificate of Occupancy from the city, and state distribution and manufacturing permits. We anticipate this being completed by the end of June.”
In addition, the TCM Distribution recently purchased and upgraded its state mandated transportation vehicle. The vehicle was purchased in March and received the state required alterations in order to assure state compliance.
In other news, the Company is pleased that the Adelanto city counsel in May approved reducing the tax on transportation, distribution, manufacturing and cannabis testing lab services from 5% down to 1%. The counsel also voted to reduce the cultivation tax from $5 per month per square foot to 42 cents per month per square foot. The dispensaries tax was also reduced from 5% down to 3%.
For further information, please visit the Company’s website at www.transcanna.com.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly owned California subsidiaries, to a range of industries including the cannabis marketplace.
On behalf of the Board of Directors
Chief Executive Officer
Telephone: (604) 609-6199
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to; the anticipation of receipt of permanent state licenses , the proposed use of the Adelanto facility, and the timing and receipt of occupancy permits. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.